TY - JOUR T1 - Airflow reversibility on long term outcomes of patients with COPD JF - European Respiratory Journal JO - Eur Respir J VL - 44 IS - Suppl 58 SP - P1815 AU - Virginia Moya AU - Ana Boldova AU - Elisa Minchole AU - Santiago Carrizo AU - Cristina Navarro AU - Allan Sam AU - Marc Miravitlles AU - Jose María Marin Y1 - 2014/09/01 UR - http://erj.ersjournals.com/content/44/Suppl_58/P1815.abstract N2 - Rationale. In COPD, post-bronchodilator spirometry is mandatory to diagnose the disease. It is uncertain whether the response to short-acting bronchodilators may also predict long-term outcomes such as hospitalisations and mortality.Methods. In the frame of BODE international cohort we studied a total of 1203 consecutive COPD patients without significant co-morbidities including a clinical diagnosis of asthma (Charlson index=0). Subjects were classified at baseline into those with positive (FEV1 >12 % and > 200ml) or negative bronchodilator test (BDT) and also in quartiles of absolute bronchodilator response to 400 mg of salbutamol. Hospital visits and overall mortality were the end points.Results. A positive BDT test was observed in 332 (27.6%) of patients. During a mean (±SD) of 69.1± 39.4 months of follow-up there were 73 (21.9%) deaths in patients with positive BDT versus 253 (28.7%) in those with negative BDT (p=0.04). In adjusted Cox regression analysis a positive BDT was significantly associated with a prolonged time to first hospitalization. When the population was divided into quartiles of response to BDT, there was a dose-response relationship with the best outcomes observed in the quartile with highest level of airflow reversibility, even after controlling for age, sex, BMI, smoking status and baseline post-bronchodilator FEV1.Conclusions.In a large population of well characterised COPD patients without significant comorbidities, those who demonstrated higher levels of reversibility after treatment with a short-acting beta-2 agonist presented better long-term outcomes even after controlling for other known prognostic factors. ER -